A 45-year-old man presents to the clinic for a routine 4-week follow-up visit. One month a… — USMLE Step 3

A $45$ -year-old man presents to the clinic for a routine $4$ -week follow-up visit. One month ago, he was diagnosed with active pulmonary tuberculosis and was started on a daily regimen of isoniazid, rifampin, pyrazinamide, and ethambutol, supplemented with pyridoxine. Today, he reports significant improvement in his symptoms; his cough has nearly resolved, and his night sweats have ceased. He has a good appetite and explicitly denies any nausea, vomiting, abdominal pain, fatigue, or dark urine. Physical examination reveals normal vital signs, no scleral icterus, and a non-tender abdomen without hepatomegaly.

Laboratory studies obtained today show the following:

Total bilirubin: $0.8 \text{ mg/dL}$ (Reference: $0.1-1.2 \text{ mg/dL}$ )
Alkaline phosphatase: $85 \text{ U/L}$ (Reference: $40-120 \text{ U/L}$ )
Aspartate aminotransferase (AST): $165 \text{ U/L}$ (Reference: $10-40 \text{ U/L}$ )
Alanine aminotransferase (ALT): $175 \text{ U/L}$ (Reference: $10-40 \text{ U/L}$ )

Which of the following is the most appropriate next step in the monitoring and management of this patient?

Continue the current medication regimen and repeat liver chemistries in 1 to 2 weeks.Answer
B
Discontinue all anti-tuberculosis medications until liver enzymes return to baseline.
C
Decrease the doses of isoniazid and rifampin by 50% to mitigate cytochrome P450-mediated interactions.
D
Obtain a right upper quadrant abdominal ultrasound.
E
Order a percutaneous liver biopsy to evaluate for irreversible hepatic necrosis.

Answer

Continue the current medication regimen and repeat liver chemistries in 1 to 2 weeks.

The correct answer involves continuing the current anti-tuberculosis therapy while scheduling close laboratory follow-up. Isoniazid, rifampin, and pyrazinamide are known to be hepatotoxic and frequently cause a transient, asymptomatic elevation in hepatic transaminases (AST and ALT) during the initial weeks of treatment. According to established guidelines, hepatotoxic anti-tuberculosis drugs should be discontinued only if serum transaminases exceed

3

times the upper limit of normal (ULN) in the presence of symptoms (e.g., nausea, vomiting, abdominal pain, jaundice), or if they exceed

5

times the ULN in an asymptomatic patient. This patient's transaminases are elevated to approximately

4

times the ULN (e.g.,

175 \text{ U/L}

versus the normal upper limit of

40 \text{ U/L}

), but he remains completely asymptomatic. Therefore, the threshold for medication discontinuation has not been met. The most appropriate management is to maintain the current regimen and monitor liver function tests closely (e.g., in

1

2

weeks) to ensure the transaminases do not cross the critical threshold.

Step-by-Step Solution

Identify the clinical scenario.

An asymptomatic patient on a standard 4-drug regimen for tuberculosis presents with elevated hepatic transaminases at a 4-week follow-up.

Establishing the patient's symptom status (asymptomatic) and current medications (hepatotoxic agents) is critical for applying the correct monitoring algorithm.

Calculate the magnitude of transaminase elevation.

AST is 165 U/L and ALT is 175 U/L. Given an upper limit of normal (ULN) of 40 U/L, the elevation is approximately 4.1 to 4.3 times the ULN.

Guidelines for drug-induced hepatotoxicity rely on precise multipliers of the upper limit of normal to dictate management.

Apply the clinical guidelines for anti-tuberculosis drug-induced hepatotoxicity.

Guidelines dictate holding hepatotoxic drugs if transaminases are >3 times the ULN in symptomatic patients, or >5 times the ULN in asymptomatic patients.

This standardized rule prevents premature discontinuation of life-saving therapy while ensuring patient safety from irreversible liver damage.

Determine the appropriate monitoring action.

Because the patient is asymptomatic and the transaminases are <5 times the ULN, the correct action is to continue therapy and perform close serial monitoring.

Continuing therapy balances the need for bacterial eradication with the observation of a frequently transient laboratory abnormality.

Key Concept

Monitoring guidelines for anti-tuberculosis drug-induced hepatotoxicity

Estimated Time:1m 30s

Question

Answer

Step-by-Step Solution

Key Concept

Common Mistakes

Topics

More questions from this topic